Planet DDS vs Regeneron Pharmaceuticals

Side-by-side comparison of AI visibility scores, market position, and capabilities

Regeneron Pharmaceuticals leads in AI visibility (92 vs 50)
Planet DDS logo

Planet DDS

ChallengerHealthtech

Dental Practice Management

Cloud-native dental practice management including Denticon for DSOs and Apteryx XVWeb for cloud imaging. Irvine CA; founded 2003;

AI VisibilityBeta
Overall Score
C50
Category Rank
#2 of 2
AI Consensus
67%
Trend
up
Per Platform
ChatGPT
54
Perplexity
51
Gemini
58

About

Planet DDS is an Irvine, California-based cloud-native dental software company that offers an integrated suite of tools for dental practices, DSOs, and dental imaging, with Denticon as its flagship cloud practice management system and Apteryx XVWeb as its cloud imaging platform. Founded in 2003, Planet DDS built Denticon as one of the first true multi-site, cloud-based dental practice management systems at a time when the market was dominated by legacy on-premise software. Denticon's multi-location architecture allows DSOs and group practices to manage enterprise-level functions—credentialing, reporting, fee schedule management, and patient record sharing across locations—from a centralized cloud platform rather than managing separate on-premise installations at each site.\n\nPlanet DDS has doubled down on the DSO market, where its cloud architecture offers significant operational advantages over legacy systems that require local servers, manual software updates, and location-by-location IT support. The company's acquisition of Apteryx, a dental imaging software business, extended its platform into digital radiography management, allowing practices to manage both clinical workflows and imaging through an integrated cloud environment. Planet DDS also acquired Legwork in 2021, a dental patient communication and marketing platform, adding patient engagement, online scheduling, and reputation management capabilities to its suite.\n\nThe DSO market has been growing rapidly as dental consolidation accelerates, and Planet DDS is positioned to benefit from practices migrating away from Dentrix and Eaglesoft to cloud-native platforms that can scale with multi-location growth. The company integrates with dental imaging sensors, intraoral cameras, and third-party lab management systems. Planet DDS competes with Carestream Dental, Curve Dental, and the Carestream/Apteryx imaging market alongside practice management leaders Dentrix and Eaglesoft, which are owned by Henry Schein.

Full profile
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

LeaderHealthcare Tech

Enterprise

Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.

AI VisibilityBeta
Overall Score
A92
Category Rank
#93 of 290
AI Consensus
66%
Trend
stable
Per Platform
ChatGPT
97
Perplexity
92
Gemini
99

About

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.

Full profile

AI Visibility Head-to-Head

50
Overall Score
92
#2
Category Rank
#93
67
AI Consensus
66
up
Trend
stable
54
ChatGPT
97
51
Perplexity
92
58
Gemini
99
43
Claude
88
52
Grok
86

Key Details

Category
Dental Practice Management
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Planet DDS
Dental Practice Management

Integrations

Only Planet DDS
Only Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.